Browse the evidence

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.

Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.

If you are on incretin medication for several years, you may notice that the weight loss and blood sugar improvements slow down or plateau. This is a known biological response (tachyphylaxis). It does not mean the drug has stopped working entirely, but it may require dose adjustments or intensified lifestyle efforts to maintain benefits.

Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.

Tirzepatide not only lowers blood sugar and helps with weight loss but may also protect your heart and blood vessels by reducing inflammation and improving lipid levels. This is especially important if you have diabetes and heart disease.

Native gut-produced GLP-1 exerts central anorectic effects via a neuroendocrine signaling mechanism involving the portal vein and vagal afferent nerves, without entering the brain.

Your body naturally produces GLP-1 after eating, which signals fullness to your brain via the vagus nerve. This is a fast, efficient system that doesn't require the hormone to cross into the brain tissue, explaining why synthetic GLP-1 drugs mimic this natural process effectively.

Roux-en-Y gastric bypass (RYGB) surgery produces distinct circulating metabolite signatures (specifically higher propionate and conjugated bile acids in good responders) that correlate with weight loss response, independent of gut microbiota composition or hunger/satiety hormone levels.

If you are considering or have had gastric bypass surgery, know that 'success' isn't just about how much weight you lose. The surgery changes your body's chemistry (specifically bile acids and gut byproducts like propionate) in ways that might improve your metabolism even if the scale doesn't move as much as expected. This means metabolic health improvements can happen independently of massive weight loss, and tracking these internal markers might be more important than just the number on the scale.

Preclinical evidence indicates that GLP-1 RAs directly improve skeletal muscle quality by reducing intramuscular fat (myosteatosis), enhancing mitochondrial biogenesis, and suppressing inflammatory markers, independent of weight loss.

Animal studies suggest GLP-1 drugs may improve the 'quality' of your muscle cells by boosting mitochondria and reducing inflammation. While this doesn't mean you'll build bigger muscles without exercise, it may help your muscles function better and recover faster, especially if you have diabetes or obesity.

GLP-1 receptor agonists exert direct anabolic and protective effects on skeletal muscle tissue, including promoting myogenesis, enhancing mitochondrial function, and reducing inflammation, which may help preserve muscle quality despite lean mass loss.

The drug may actively help protect muscle quality at a cellular level, but this does not guarantee muscle mass preservation without active lifestyle interventions.

Cerebral CCK acts as a neurotransmitter involved in memory and anxiety regulation, with knockout mice showing memory loss and increased anxiety, while exogenous CCK administration can induce panic attacks.

CCK is not just a gut hormone; it works in the brain to regulate anxiety and memory. While high doses can induce panic, natural CCK signaling may help modulate these states. This highlights the gut-brain axis.

Bariatric surgery (Roux-en-Y gastric bypass) reduces the incidence of heart failure by 2-5 times compared to non-surgical patients, as observed in large Swedish registries.

Bariatric surgery significantly lowers the risk of developing heart failure (by 2-5 times) compared to non-surgical management in obese patients.

Calorie restriction-induced weight loss does not restore or alter the secretion of appetite-inhibiting gut hormones (GLP-1, PYY, CCK, GIP, NT, SST) or their gene expression in the small intestine of obese subjects.

If you have lost weight, do not expect your hunger hormones to normalize. Your body may still signal hunger as strongly as it did when you were heavier. This biological persistence is a key reason for weight regain, so you must rely on external strategies (dietary structure, behavioral habits) to manage appetite, as your internal hormonal signals will not naturally support maintenance.

In individuals with normal glucose tolerance (NGT), carbohydrate-modified diets (low glycemic load or high fiber) do not provide a significant weight loss advantage over high-carbohydrate or control diets, and may even result in greater weight regain on high glycemic load diets.

If you have normal blood sugar levels, switching to a low-carbohydrate or low-glycemic diet is unlikely to give you a weight loss advantage over a standard balanced diet. You may even regain weight faster if you switch to a high-glycemic diet, but a low-glycemic diet offers no special benefit. Focus on sustainable eating habits rather than strict carbohydrate restriction.

Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.

If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.

Gold-standard T2DM medications (metformin, SGLT2 inhibitors, GLP-1 agonists) modulate the redox state of skeletal muscle, potentially restoring metabolic function and insulin sensitivity.

Standard diabetes medications like metformin and GLP-1 agonists do more than lower blood sugar; they also interact with the redox state of your muscles. This interaction may help restore insulin sensitivity, offering a benefit beyond simple glycemic control.

Administration of the triple agonist peptide GEP44 to diet-induced obese rats produces greater reductions in body weight and food intake compared to the GLP-1 receptor agonist liraglutide, while avoiding the nausea and malaise associated with high-dose GLP-1RAs.

This preclinical data suggests that combining GLP-1 activity with Neuropeptide Y1 and Y2 receptor agonism may offer a path to more effective weight loss than current GLP-1 drugs alone, potentially without the common side effect of nausea. This is not yet a human treatment but highlights a promising direction for peptide-based obesity therapies.

GEP44 promotes insulin-independent glucose uptake in muscle tissue via Y1 receptor agonism, distinct from the insulin-dependent pathway.

This mechanism suggests that future obesity drugs might improve blood sugar control in muscles even without triggering insulin release, potentially offering benefits for insulin resistance.

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Older adults may experience higher rates of adverse events and treatment intolerance with AOMs compared to younger adults, particularly gastrointestinal issues and risks related to dehydration and falls.

Be aware that older adults may experience more side effects from weight loss medications, such as nausea or dizziness. This can lead to dehydration or falls. It is important to work closely with a doctor to manage these side effects.

In visceral adipose tissue (VAT) of individuals with obesity and prediabetes, GLP-1, GIP, and glucagon distinctively modulate metabolic profiles, with GLP-1 shifting metabolism toward anaerobic glycolysis (increased lactate/alanine) and the other two hormones promoting oxidative phosphorylation (increased pyruvate consumption), suggesting an overall improvement in mitochondrial function.

For individuals with obesity and prediabetes, gut hormones like GLP-1, GIP, and glucagon do not act uniformly on fat tissue. GLP-1 appears to shift VAT metabolism toward anaerobic pathways (increasing lactate and alanine), while GIP and glucagon may support mitochondrial function by increasing pyruvate consumption. This suggests that the metabolic health status (specifically prediabetes) significantly alters how fat tissue responds to these hormones, potentially explaining varied clinical outcomes in weight loss and glycemic control therapies.

Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.

GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.

Targeting endogenous enteroendocrine cell (EEC) secretion to mimic postprandial hypersecretion of GLP-1 and other GI hormones offers a potential treatment for obesity and type 2 diabetes that avoids the side effects of exogenous GLP-1-based drugs.

Current research suggests that stimulating your gut to release its own GLP-1 (perhaps through specific nutrients or future drugs) might help with weight loss and blood sugar control without the nausea or nutrient malabsorption seen with current GLP-1 injections. This is still experimental.

Semaglutide induces adipose tissue remodeling in Type 2 Diabetes by promoting mitochondrial biogenesis, inducing beige adipocyte programming, and reducing visceral adiposity, leading to improved systemic insulin sensitivity and reduced ectopic fat deposition.

For individuals with T2DM or obesity, semaglutide offers benefits that go beyond simple weight loss. It actively remodels fat tissue, particularly visceral fat, making it more metabolically active and less inflammatory. This leads to improved insulin sensitivity and reduced liver fat, which are critical for long-term metabolic health. The medication is taken once weekly, with doses tailored to whether the goal is managing diabetes (up to 1.0 mg) or weight loss (up to 2.4 mg).

Tirzepatide promotes sustained improvements in skeletal muscle mitochondrial respiration and ATP production under lipotoxic conditions, whereas semaglutide and cagrilintide cause transient suppression that resolves over time.

If you are using incretin-based therapies like tirzepatide, this in vitro evidence suggests your muscle cells may become more efficient at producing energy over time, even under metabolic stress. While other drugs in this class (semaglutide, cagrilintide) show temporary dips in mitochondrial function, tirzepatide appears to enhance it. This supports the importance of resistance training to leverage these cellular adaptations for maintaining muscle quality.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.